Voyager Therapeutics (VYGR) Cash & Equivalents (2014 - 2026)

Voyager Therapeutics has reported Cash & Equivalents for 13 years, with the latest figure at $43.3 million in Q1 2026.

• Quarterly Cash & Equivalents fell 42.06% year-over-year to $43.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.3 million (down 42.06% YoY) and the FY2025 annual result came in at $65.3 million, down 8.5% from the prior year.
• Cash & Equivalents retreated to $43.3 million in Q1 2026 per VYGR's latest filing, from $65.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $268.3 million in Q1 2023 and troughed at $43.3 million in Q1 2026.
• A 5-year average of $101.7 million and a median of $76.1 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents surged 211.88% in 2023, then sank 68.84% in 2024.
• Over 5 years, Cash & Equivalents stood at $99.0 million in 2022, then plunged by 30.47% to $68.8 million in 2023, then gained by 3.73% to $71.4 million in 2024, then declined by 8.5% to $65.3 million in 2025, then slumped by 33.67% to $43.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $43.3 million, $65.3 million, and $45.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.